Results 221 to 230 of about 650,104 (308)

The Tumor Immune Microenvironment in Endometrial Cancer: Composition, Molecular Subtypes, and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Endometrial cancer (EC), a major gynecologic malignancy and a representative “cold tumor”, exhibits a tumor immune microenvironment (TIME) influenced by a broad range of cellular and molecular elements, immunosuppressive signals, and pathways of immune evasion.
Jingxuan Ye, Yashi Shi, Alexander Mustea, Xiaodan Mao, Pengming Sun   +4 more
wiley   +1 more source

The pterocarpan (+)-PTC modulates cytoskeletal proteins and induces apoptosis in metastatic castration-resistant prostate cancer: a proteomic perspective. [PDF]

Front Pharmacol
de Brito Vieira Neto J, Moraes de Farias K, Alves Sales SL, Melo VB, Nascimento Macêdo SM, Koscky Paier CR, Bezerra MJ, Moura AA, Carvalho HF, Domingos de Sousa F, Aquino A, de Oliveira Monteiro AC, Martins-de-Souza D, Banwell MG, Miranda Furtado CL, Pessoa C.   +15 more
europepmc   +1 more source

Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies

Obesity Science &Practice, Volume 12, Issue 3, June 2026.
ABSTRACT Introduction Obesity increasingly influences treatment outcomes in urological malignancies (metastatic bladder cancer (BC), renal cell cancer (RCC), and prostate cancer (PC)). This study evaluated the impact of obesity on survival in patients with major metastatic urological cancers receiving systemic therapy.
A. Handke, M. Silberg, C. Orf, C. Loeffelholz, P. Bach, S. Berg, F. Roghmann, K. H. Tully   +7 more
wiley   +1 more source

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer. [PDF]

BMC Cancer
Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É, Guillemette C.   +16 more
europepmc   +1 more source

Combining radiotherapy with CAR‐T cell therapy for solid tumors: Challenges, mechanisms, and future directions

Precision Radiation Oncology, Volume 10, Issue 2, Page 192-204, June 2026.
Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu, Xingyu Zhou, Jiao Xue, Xiaokang Zhang, Songbing Qin   +4 more
wiley   +1 more source

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer. [PDF]

Cancer Res
Kittane S, Ladewig E, Li T, Love JR, Blawski R, Gao Y, Arruabarrena-Aristorena A, Zhao P, Dalrymple SL, Liu H, Guo X, Sallaku M, Kelkar N, Garcia-Martinez L, Carmona Sanz J, Chen W, Stoudmann C, Baldino L, Razavi-Mohseni M, Kalemi I, Beer MA, Castel P, Brennen WN, Scaltriti M, Morey L, Cocco E, Ji H, Chan HM, Battle A, Leslie CS, Karthaus WR, Toska E.   +31 more
europepmc   +1 more source

A new perspective on radiotherapy in the comprehensive treatment of cancer

Precision Radiation Oncology, Volume 10, Issue 2, Page 165-183, June 2026.
Radiotherapy remains a key component in the comprehensive management of cancer. Its effectiveness is significantly improved through strategic combinations with chemotherapy, targeted therapy, and immunotherapy, providing a range of therapeutic outcomes from cure to palliative care.
Yingze Ma, Hongxuan Yu, Shijie Shang, Shixin Shan, Dawei Chen   +4 more
wiley   +1 more source

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer. [PDF]

Cell Death Dis
Yanushko D, Pichot A, Vincent A, Keime C, Laverny G, Metzger D.   +5 more
europepmc   +1 more source